Peptide impurities and why they matter
Deletion sequences, oxidation products, aggregates and synthesis byproducts — and why an impurity profile belongs on a COA.
Deletion sequences, oxidation products, aggregates and synthesis byproducts — and why an impurity profile belongs on a COA.

Peptides are chains of amino acids built one residue at a time. That synthesis is imperfect, and the imperfections are the impurities. Understanding what they are explains both why a single purity number is not enough and why regulators single peptides out for immunogenicity concern.
The impurity families. A deletion sequence is a chain missing one or more amino acids — the synthesis skipped a residue. A truncated sequence is a chain cut short — the synthesis stopped early. Oxidation products form when sensitive residues react with oxygen. Aggregates are chains stuck to each other, clumped together rather than separate. And synthesis byproducts are the leftover chemistry — protected fragments, coupling reagents, side-reaction products. Each family is chemically different from the intended peptide, and each can behave differently in the body.
Why they matter. The concern is immunogenicity — an unwanted immune response to something that is not the intended molecule. The FDA's 2023 action on BPC-157 cited the possibility of immunogenicity for certain routes and the complexity of peptide-related impurities and API characterization. A 2024 FDA advisory committee presentation went further: impurities in peptides, including aggregates, can raise immunogenicity risk, which can include life-threatening reactions such as anaphylaxis, and controlling them requires sophisticated manufacturing and testing. The structural reason is that the immune system can recognize a mis-shaped or clumped peptide where it would ignore the correct, soluble chain.
What this means for a certificate. A result that says "purity 99%" tells you the main peak is 99% of total area. It does not tell you what the remaining 1% is — and the remaining 1% is exactly where the immunogenicity risk lives. An impurity profile is the answer: it characterizes what else is in the vial, not just how much of it there is. Paired with identity (which confirms the main component is the intended chain) and purity (which quantifies the main component's share), an impurity profile is what turns a purity number into a characterization.
This is the connection between the chemistry and the regulator. The FDA's difficulty with peptides is not that they are new; it is that the impurities are hard to see and hard to characterize, and the hard-to-see impurities are the ones that drive the risk. A COA that reports identity, purity, and an impurity profile is doing the characterization work the FDA describes as difficult — which is why an impurity profile belongs on the certificate and not just a single purity figure.
Cites: FDA 503A category 2 list (2023); FDA PCAC presentation (2024).
Regulator2024An FDA advisory committee presentation explained how peptide impurities, including aggregates, can raise immunogenicity risk.
Study2012A 2012 sterility failure in compounded steroid injections sickened more than 700 people across 20 states and killed 64.
Explainer2024Arsenic, cadmium, lead and mercury — where they come from, how they are measured, and the limits that apply.